VISSIT Intracranial Stent Study for Ischemic Therapy

Codman & Shurtleff

Status and phase

Terminated

Phase 3

Phase 2

Conditions

Ischemic Stroke

Transient Ischemic Attack

Treatments

Drug: Aspirin and Clopidogrel (Medical therapy)

Device: Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00816166

G080051

VISSIT CA-2007-01

Details and patient eligibility

About

The main objective of this study is to prospectively evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse Neurovascular Stent System in a multicenter, randomized clinical trial.

A secondary objective of this study is to evaluate the impact of stenting in the neurovasculature to treat cerebral ischemia on other outcomes such as hospital length of stay, charges, and costs.

Full description

1.1 Study Hypothesis Treatment of cerebral or retinal ischemia due to plaque in the neurovasculature using the PHAROS Vitesse Stent System plus medical therapy will provide additional clinical benefit over medical therapy alone.

1.2 Primary Effectiveness Endpoint

The primary effectiveness endpoint consists of a composite of the two following outcomes:

Stroke in the same territory (distal to the target lesion) as the presenting event within 12 months of randomization
Hard TIA in the same territory (distal to the target lesion) as the presenting event from day 2 through month 12 post-randomization

1.3 Safety Outcomes

Safety outcomes to be collected and reported as part of the overall risk-to-benefit profile for this device are:

Stroke in any territory within 30 days of randomization
Death from any cause within 30 days of randomization
Hard TIA in any territory occurring after a 24 hour post-procedure stabilization period (days 2-30) since the recovery from anesthesia can mask accurate assessment of possible TIA symptoms.
Intracranial hemorrhage within 30 days of randomization

1.4 Other Outcomes

Stent Success - PHAROS Vitesse stent deployed across target lesion with residual stenosis 0-20%
Percentage of Stent Group Subjects with any (symptomatic or asymptomatic) in-stent restenosis ≥ 70% confirmed by angiogram at 12 months
Percentage of Stent Group Subjects with symptomatic in-stent restenosis ≥ 70% confirmed by angiogram at 12 months
Percentage of Medical Therapy Group Subjects with interventional procedure (e.g., angioplasty or stent) at 12 months
Comparison of NIHSS scores between treatment arms
Comparison of mRS scores between treatment arms

Enrollment

125 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject has at least one neurovascular lesion (70-99%) stenosis [internal carotid, middle cerebral, vertebral artery (C4-BA), and/or basilar artery] symptomatic with a hard TIA or stroke attributable to the territory of the lesion within the past 30 days. An intracranial tandem lesion (50-99%) stenosis may be treated if normal artery segment is sufficient length to avoid overlapping stents.
Target vessel diameter / lesion length measurements are within one of the below per angiogram:
- Vessel diameter is ≥ 2.0 mm and < 2.5 mm / lesion length is ≤ 16 mm, or
- Vessel diameter is ≥ 2.5 mm and < 3.0 mm / lesion length is ≤ 18 mm, or
- Vessel diameter is ≥ 3.0 mm and < 4.5 mm / lesion length is ≤ 26 mm, or
- Vessel diameter is ≥ 4.5 mm and ≤ 5.0 mm / lesion length is ≤ 31 mm
Subject has normal artery adjacent to each stenosis; diameter 2.0 mm - 5.0 mm
Subject age is 18-85 years
Life expectancy is at least 2 years
Subject 's mRS score is ≤ 3
Subject is available for study follow-up visits (e.g., lives within 3 hours of research center)
Subject is willing and cognitively able to provide Informed Consent (consent may be indicated verbally and signed by neutral witness if stroke has impaired hand or visual function)

Exclusion criteria

Subject has contraindications for balloon expandable stent, e.g.
- Extreme tortuosity at, or proximal to, target lesion,
- More than 2 lesions with > 50% stenosis (including vertebral ostia and common carotid disease),
- Carotid or vertebral dissection
CT scan or MRI evidence of any of the following:
- Intracranial hemorrhage of type PH1 or PH2
- Subdural or epidural hemorrhage
- Mass effect, or
- Intracranial tumor (except small meningioma)
Subject has a previous stent in the territory of the target lesion(s)
Subject has a previous coil or clip placed in the territory of the target lesion within 6 months
Subject has a potential source of cardiac embolism requiring anticoagulation therapy (e.g., atrial fibrillation, intracardiac thrombus or vegetation, significant mitral stenosis, mechanical heart valve, congestive heart failure with EF <30%, or endocarditis)
Subject has concurrent intracranial pathology, e.g.
- Moyamoya
- Vasculitis documented by biopsy results
- Ruptured Aneurysm
- Unruptured aneurysm > 7mm
Subject has uncontrolled hypertension (systolic >185 mmHg or diastolic >110 mmHg)
Hemoglobin < 10 g/dL; platelet count < 100,000; or INR > 1.5 (e.g., use of warfarin)
Subject has an uncorrectable bleeding diathesis
Subject's neurological status is unstable and rapidly declining (NIHSS score increased > 4 points within 48 hours prior to randomization)
Subject has a contraindication for combination antithrombotic treatment (e.g., clopidogrel and aspirin) such as peptic ulcer disease
Subject history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)
Subject has a known history contraindicating contrast dye or iodine (vs. sensitivity which can be safely controlled by antihistamine, steroid, etc.)
Subject is pregnant or plans to become pregnant in the next 12 months
Myocardial infarction within past 3 months
Treatment with tPA or other thrombolytic agent within 48 hours prior to randomization
Major surgery or trauma within 2 weeks prior to randomization
Enrollment in another investigational device or drug study that may confound the results